New research suggests there may someday be a role for ibuprofen in providing older adults with lasting immunity against RSV, a virus commonly associated with infants and young kids that also rivals the flu as a dangerous wintertime infection for the elderly.
Respiratory syncytial virus, commonly called RSV, usually affects very young children in the winter months. But this year, physicians are treating an unusual, out-of-season surge both in California and across the country.
Monroe Carell Jr. Children’s Hospital at Vanderbilt is seeing a spike in respiratory illnesses, especially RSV (respiratory syncytial virus) and parainfluenza, which cause croup and bronchiolitis in young children and flu-like symptoms in older children and adults
A new Houston Methodist study shows a rapid return of seasonal respiratory viruses after COVID-19 restrictions were relaxed in Texas, demonstrating the apparent effectiveness of masking, distancing and other precautionary measures at stopping the spread of respiratory illnesses. This rise in infections to pre-pandemic levels followed updated governmental guidelines lifting mask, distancing and occupancy requirements.
By figuring out how a common virus hides from the immune system, scientists have identified a potential vaccine to prevent sometimes deadly respiratory infections in humans.
While it can be difficult to decipher symptoms, Michele Walsh, MD, assistant professor of Pediatrics and medical director of the Pediatric Emergency Department at Children’s Hospital, offers tips on when it is best to bring a child to an emergency department (ED) versus making a call or visit to the family pediatrician.
A vaccine for the common and sometimes deadly RSV (respiratory syncytial virus) has been elusive, but scientists say a new discovery puts them much closer to success.
Mesa Biotech Inc., a privately-held, molecular diagnostic company that has developed an affordable, sample-to-answer, CLIA-waived PCR (polymerase chain reaction) testing platform designed specifically for point-of-care (POC) infectious disease diagnosis, today announced the launch of its respiratory syncytial virus test (RSV). Mesa will demonstrate its expanded, novel Accula™ Test System at the 71st American Association of Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Expo. The Accula System’s RSV and Flu A/Flu B molecular tests will be on exhibit in Booth 3902. Sekisui Diagnostics distributes both products in the US under the Silaris™ brand.